|
Pfizer Comments on ORAL Sync Tofacitinib Data in EULAR Abstract LB0005
|
27 April 2011 |
|
Pfizer Announces Top-Line Results of Third Phase 3 Clinical Trial of Tofacitinib (CP-690,550)
|
18 April 2011 |
|
Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of Dimebon in Huntington Disease
|
12 April 2011 |
|
Pfizer to Sell Capsugel to KKR
|
05 April 2011 |
|
Pfizer Posts Details Of Interactions With U.S. Health Care Professionals And Researchers In 2010
|
01 April 2011 |
|
SPIRIVA HandiHaler Prolonged Time To First COPD Exacerbation
|
23 March 2011 |
|
Pfizer Announces Primary Endpoints Met in Second Phase 3 Clinical Trial of Tofacitinib
|
06 March 2011 |
|
New AVERROES Data Demonstrate Investigational Apixaban Superior to Aspirin
|
13 February 2011 |
|
Pfizer To Acquire Ferrosan's Consumer Healthcare Business
|
07 February 2011 |
|
New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan
|
06 February 2011 |
|
Pfizer Reports Fourth-Quarter and Full-Year 2010 Results
|
01 February 2011 |
|
Pfizer Completes Tender Offer For Shares Of King Pharmaceuticals, Inc.
|
31 January 2011 |
|
Pfizer Submits Applications to Expand the Use of Prevnar 13® to Adults 50 and Older
|
22 December 2010 |
|
Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc.
|
15 December 2010 |
|
Young Children In Developing World Receive Accelerated Access to Pfizer's Prevenar 13 Vaccine
|
12 December 2010 |
|
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib
|
06 December 2010 |
|
Pfizer Launches Global Centers for Therapeutic Innovation
|
18 November 2010 |
|
Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity
|
15 November 2010 |
|
Alpine Mountaineer and Alzheimer's Advocate to Climb Highest Peak on Each Continent
|
09 November 2010 |
|
Pfizer Reports Third-Quarter 2010 Revenues of $16.2 Billion
|
03 November 2010 |